Bi‐specific T‐cell engagers and chimaeric antigen receptor T cells against CD19 have demonstrated the efficacy of immunotherapeutic approaches to treat ALL.17, 18, 19, 20. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.